Arcutis Biotherapeutics shares are trading higher after the company announced that ZORYBE cream 0.3% for plaque psoriasis in adults and adolescents is now covered as a preferred tier product on CVS Caremark's largest national commercial formularies.
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics announced that its ZORYBE cream 0.3% for plaque psoriasis is now a preferred tier product on CVS Caremark's largest national commercial formularies. This has led to a rise in the company's share prices.
July 17, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics' shares are trading higher after the announcement of ZORYBE cream being included as a preferred product on CVS Caremark's formularies.
The inclusion of Arcutis Biotherapeutics' ZORYBE cream as a preferred product on CVS Caremark's formularies implies a potential increase in sales and revenue for the company. This positive news has led to an increase in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100